Cargando…
EGFR突变调控肺腺癌PD-L1表达的分子机制研究进展
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors were landmarks in the treatment of non-small cell lung cancer (NSCLC). However, the regulation mechanisms of PD-L1 express...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247000/ https://www.ncbi.nlm.nih.gov/pubmed/30454551 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.11.10 |